PHOTO
Image used for illustrative purpose. Getty Images
US-Kenyan company Kentegra Biotechnology Holdings is seeking proposals for conducting a feasibility study to assess the viability of developing a full-scale pyrethrum refined extract facility (PRE) in Nairobi, the company said in a tender document.
The company is seeking technical proposals from qualified US firms to provide expert consulting services to perform the feasibility study for the third phase.
The Kenyan company received a grant of $661,000 from the US Trade and Development Agency (USTDA) in September 2022.
The study will support Kentegra in expanding its production of Pyrethrum, a natural active ingredient from the chrysanthemum flower, which is used as an active ingredient in home biocide, agricultural and pharmaceutical pesticides.
The company recently completed a manufacturing expansion in the second phase alongside the factory in the first phase, which more than doubled its extraction and refining capacity.
The third phase will have additional manufacturing efficiencies and be a larger, permanent, and purpose-built facility. It will also include milling, extraction, and refining plants, utilities, a warehouse, and offices.
The completion of the third phase will significantly increase Kentegra’s production, making it the second-largest PRE producer in the world.
The proposal submission deadline is 28 March 2023, the document said.
(Writing by P Deol; Editing by Anoop Menon)
